Autophagy inhibition synergizes with calcium mobilization to achieve efficient therapy of malignant gliomas
Open Access
- 14 June 2018
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 109 (8) , 2497-2508
Abstract
Autophagy plays a critical role in tumorigenesis, but how autophagy contributes to cancer cells’ responses to chemotherapeutics remains controversial. To investigate the roles of autophagy in malignant gliomas, we used CRISPR/CAS9 to knock out the ATG5 gene, which is essential for autophagosome formation, in tumor cells derived from patients with glioblastoma. While ATG5 disruption inhibited autophagy, it did not change the phenotypes of glioma cells and did not alter their sensitivity to temozolomide, an agent used for glioblastoma patient therapy. Screening of an anticancer drug library identified compounds that showed greater efficacy to ATG5‐knockout glioma cells compared to control. While several selected compounds, including nigericin and salinomycin, remarkably induced autophagy, potent autophagy inducers by mTOR inhibition did not exhibit the ATG5‐dependent cytoprotective effects. Nigericin in combination with ATG5 deficiency synergistically suppressed spheroid formation by glioma cells in a manner mitigated by Ca2+ chelation or CaMKK inhibition, indicating that, in combination with autophagy inhibition, calcium‐mobilizing compounds contribute to efficient anticancer therapeutics. ATG5‐knockout cells treated with nigericin showed increased mitochondria‐derived reactive oxygen species and apoptosis compared to controls, indicating that autophagy protects glioma cells from mitochondrial reactive oxygen species‐mediated damage. Finally, using a patient‐derived xenograft model, we demonstrated that chloroquine, a pharmacological autophagy inhibitor, dramatically enhanced the efficacy of compounds selected in this study. Our findings propose a novel therapeutic strategy in which calcium‐mobilizing compounds are combined with autophagy inhibitors to treat patients with glioblastoma.Keywords
Funding Information
- Japan Society for the Promotion of Science (16H01199, JP17K07160)
- Ministry of Education, Culture, Sports, Science and Technology (15H02361)
- Japan Agency for Medical Research and Development (18cm0106104h0003)
This publication has 44 references indexed in Scilit:
- MST4 Phosphorylation of ATG4B Regulates Autophagic Activity, Tumorigenicity, and Radioresistance in GlioblastomaCancer Cell, 2017
- Early effects of the antineoplastic agent salinomycin on mitochondrial functionCell Death & Disease, 2015
- Mitophagy is primarily due to alternative autophagy and requires the MAPK1 and MAPK14 signaling pathwaysAutophagy, 2015
- Withdrawal of Essential Amino Acids Increases Autophagy by a Pathway Involving Ca2+/Calmodulin-dependent Kinase Kinase-β (CaMKK-β)Journal of Biological Chemistry, 2012
- Inhibition of Mitochondria- and Endoplasmic Reticulum Stress-Mediated Autophagy Augments Temozolomide-Induced Apoptosis in Glioma CellsPLOS ONE, 2012
- A Combined Preclinical Therapy of Cannabinoids and Temozolomide against GliomaMolecular Cancer Therapeutics, 2011
- Akt and Autophagy Cooperate to Promote Survival of Drug-Resistant GliomaScience Signaling, 2010
- Autophagy Is Essential for Mitochondrial Clearance in Mature T LymphocytesThe Journal of Immunology, 2009
- Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cellsCell Death & Differentiation, 2004
- Therapy of glioblastoma multiforme improved by the antimutagenic chloroquineNeurosurgical Focus, 2003